{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.079","upperLimit":"0.420","value":"0.227"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"-Disease relapse occurs in recipients who entered transplant in CR. Progression occurs in recipients with existent disease at transplant who meet criteria for progressive disease post-transplant. A recipient will be considered relapsed when there is a recurrence of the original malignant disease after transplantation. Date of relapse/progression is defined as the date at which the first observation of hematologic, radiographic, or cytogenetic changes which signify progression/relapse is made","dispersionType":"95% Confidence Interval","groups":[{"description":"-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10\\^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10\\^6 CD34+ cells/kg and at least ≥ 2 x 10\\^6 CD34+ cells/kg from the combined collections.","id":"OG000","title":"Arm 1: Donors"},{"description":"-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0","id":"OG001","title":"Arm 2: Recipients"}],"paramType":"NUMBER","populationDescription":"Donors are not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"At 1 year post-tranplantation","title":"Cumulative Incidence of Disease Relapse/Progression After Transplantation of Hematopoietic Cells Mobilized With BL-8040 (Arm 2 Recipients Only)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}